Introduction
============

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)[^3^](#FN2){ref-type="fn"} is a positive-sense RNA virus and the causative agent of coronavirus disease 2019 (COVID-19) ([@B1], [@B2]). The initial outbreak in December 2019 in Wuhan, China, was declared a pandemic by the World Health Organization on March 10, 2020 ([@B3]). Antiviral treatments are urgently needed to relieve the burden on healthcare systems worldwide. Effective therapeutics are expected to reduce mortality and hospitalizations. In the absence of a vaccine, antiviral therapeutics could also be utilized prophylactically to protect vulnerable populations, including those who are frequently exposed to the virus. Despite the earlier outbreaks of SARS in 2003 and Middle East respiratory syndrome (MERS) in 2012, coronavirus-specific antivirals have yet to advance into clinical trials. At this point, the focus is on compounds with a demonstrated broad spectrum of antiviral activities and on drugs developed for other therapeutic purposes with evidence of acting also against coronaviruses. Several of these compounds are currently being assessed in randomized controlled clinical trials, including remdesivir (RDV; formerly GS-5734) ([@B4]).

RDV is a phosphoramidate prodrug of a 1′-cyano-substituted nucleotide analogue ([@B5]). Its triphosphate form (RDV-TP) resembles ATP and is used as a substrate of several viral RNA-dependent RNA polymerase (RdRp) enzymes or complexes ([@B6][@B7][@B9]). The compound has shown broad-spectrum *in vitro* and *in vivo* antiviral activity against nonsegmented negative-sense RNA viruses of the *Filoviridae* (*e.g.* Ebola virus (EBOV)) ([@B5], [@B8]) and *Paramyxoviridae* (*e.g.* Nipah virus (NiV)) families ([@B7], [@B10], [@B11]), as well as *in vitro* activity against viruses in the *Pneumoviridae* (*e.g.* respiratory syncytial virus (RSV)) family ([@B10]). Antiviral activity against a broad spectrum of coronaviruses, including SARS-CoV and MERS-CoV, was subsequently demonstrated both *in vitro* and in animal models ([@B6], [@B12][@B13][@B15]). No *in vitro* inhibition was reported for several segmented negative-sense RNA viruses of the *Arenaviridae* family (*e.g.* Lassa virus (LASV)) and the *Bunyavirals* order (formerly the family *Bunyaviridae*; *e.g.* Crimean Congo hemorrhagic fever virus) ([@B10]). RDV was also recently tested in a randomized controlled trial during the 2019 Ebola outbreak in the Democratic Republic of the Congo ([@B16]). Although two antibody-based treatments showed superior efficacy, mortality in the RDV arm was lower than the overall mortality rate of the outbreak, and human safety data are now available ([@B16]). Inhibition of MERS-CoV replication and therapeutic efficacy of RDV was also demonstrated in mouse and rhesus macaque models ([@B13], [@B15]).

Progress has been made in elucidating the mechanism of action of RDV-TP. RDV-TP competes with ATP for incorporation by the EBOV RdRp complex composed of the L protein and VP35 ([@B9]). Steady-state kinetics reveal that incorporation of ATP is slightly more efficient compared with RDV-TP. In contrast to classic chain terminators, inhibition is not seen immediately following the incorporated RDV-TP, and the existence of a 3′-OH group allows the nucleophilic attack on the next incoming nucleotide. Studies with EBOV RdRp, RSV RdRp, and NiV RdRp have indicated that RNA synthesis is terminated after a few more nucleotide incorporation events ([@B7], [@B9]). RDV-TP incorporation at position *i* commonly yields delayed chain termination between positions *i*+3 and *i*+5. We have recently expressed and purified an active complex composed of MERS nonstructural proteins nsp8 and nsp12 ([@B17]). With the limitations of steady-state kinetic measurements, we showed that incorporation of RDV-TP is more efficient than ATP, and delayed chain termination is observed specifically at position *i*+3. Potential inhibitory effects of RDV-TP on SARS-CoV RdRp or on SARS-CoV-2 RdRp have not been studied. Active SARS-CoV RdRp was shown to form a complex composed of nsp7, nsp8, and nsp12, whereby nsp7 and nsp8 were connected with a linker ([@B18]). Structures of complexes with the three subunits were recently determined using cryo-EM ([@B19]).

Here, we expressed SARS-CoV and SARS-CoV-2 RdRp complexes in insect cells and monitored RNA synthesis on short model primer/templates during elongation. We demonstrate that RDV-TP inhibits SARS-CoV RdRp and SARS-CoV-2 RdRp with the same potency and mechanism of action. The ability to efficiently compete with the natural counterpart ATP is a favorable property of RDV-TP. We have tested in the same context several other nucleotide analogues and commonly observe that incorporation of the natural nucleotide is considerably preferred. Favorable selectivity for the RDV-TP over ATP and delayed chain termination at position *i*+3 are key elements of a refined mechanism of inhibition observed with SARS-CoV, MERS-CoV, and SARS-CoV-2 RdRp complexes.

Results
=======

Expression of SARS-CoV and SARS-CoV-2 RdRp complexes
----------------------------------------------------

We have recently generated recombinant MERS-CoV RdRp from a bacmid containing nsp5, -7, -8, and -12 ([@B17]). Expression of this construct in insect cells resulted in the nsp5-7-8-12 polyprotein processed by the nsp5 protease. Nickel-nitrilotriacetic acid affinity chromatography yielded an active binary nsp8/12 RdRp complex. We therefore expressed SARS-CoV and SARS-CoV-2 RdRp from bacmids containing the equivalent nsp5, -7, -8, and -12 sequences. This approach yielded binary complexes with nsp8 and nsp12, as described previously for MERS-CoV ([@B17]). We also expressed mutant enzymes with amino acid substitutions in the conserved motif C of nsp12 (SDD to SNN) to inactivate the catalytic site ([Fig. 1](#F1){ref-type="fig"}*A*). WT and mutant enzymes were tested for RNA synthesis on short model primer/templates mimicking a random elongation complex. Incorporation of a radiolabeled nucleotide allows gel-based detection of reaction products. Whereas WT SARS-CoV and SARS-CoV-2 RdRp complexes were able to synthesize RNA from a 4-mer primer and a 14-mer template, the corresponding active-site mutants showed no template-base--specific nucleotide incorporation ([Fig. 1](#F1){ref-type="fig"}*B*). These data confirm that RNA synthesis activity is mediated by nsp12.

![**Expression, purification, and characterization of the SARS-CoV and SARS-CoV-2 RdRp complexes.** *A*, SDS-PAGE migration pattern of the purified enzyme preparations stained with Coomassie Brilliant Blue G-250 dye. Bands migrating at ∼100 kDa and ∼25 kDa contain nsp12 and nsp8, respectively. *B*, RNA synthesis on a short model primer/template substrate. Template and primer were both phosphorylated (*p*) at their 5′-ends. A radiolabeled 4-mer primer serves as a marker (*m*). *G* indicates incorporation of the radiolabeled nucleotide opposite template position 5. RNA synthesis was monitored with the purified RdRp complexes representing WT (*wt*, motif C = SDD) and the active-site mutant (motif C = SNN).](zbc9992023900001){#F1}

Selectivity measurements of RDV-TP with related and distant RdRp enzymes
------------------------------------------------------------------------

The ratio of Michaelis--Menten steady-state kinetic parameters *V*~max~/*K~m~* for a single incorporation of a natural nucleotide over a nucleotide analogue defines the selectivity. With the limitations of a steady-state approach, a selectivity value lower than 1 suggests that the analogue is incorporated more efficiently than the natural NTP. Conversely, a selectivity value higher than 1 suggests that the analogue is incorporated less efficiently than the natural NTP. This approach enables comparisons of data with different enzymes and different nucleotide analogues. This approach does not provide distinct information on inhibitor binding, catalysis, or enzyme dissociation from its nucleic acid substrate. To measure selectivity for RDV-TP incorporation, we determined the steady-state kinetic parameters for single nucleotide incorporations compared with ATP ([Fig. S1](https://www.jbc.org/cgi/content/full/RA120.013679/DC1) and [Table 1](#T1){ref-type="table"}). Previously, we reported a selectivity value of 0.35 for RDV-TP incorporation with MERS-CoV RdRp ([@B17]). SARS-CoV and SARS-CoV-2 also showed low values in a similar range (0.32 and 0.26, respectively). For EBOV, RSV, and LASV enzymes, we measured higher values (4.0, 2.7, and 23, respectively). Because the RNA template used to measure selectivity in this study differs from the sequence previously used to study inhibition of EBOV and RSV RdRp ([@B9]), we repeated these experiments with EBOV and the current RNA template. The observed selectivity value of 4 is in good agreement with our previous measurement of 3.8 ([@B9]). LASV RdRp showed the highest selectivity value for RDV-TP of 23-fold, which provides evidence for target specificity. The combined results suggest that the ability of RDV-TP to compete with ATP is most pronounced with the coronavirus RdRp complexes.

###### 

**Selectivity values for Remdesivir (RDV-TP) with related and distant RdRp enzymes**

                                                    ATP                                           RDV-TP               Selectivity*^[c](#TF1-3){ref-type="table-fn"}^*                                          
  ------------------------------------------------- --------------------------------------------- -------------------- ------------------------------------------------- --------- -------------------- ------- ---------
                                                                                                  μ*[m]{.smallcaps}*                                                               μ*[m]{.smallcaps}*           *-fold*
  MERS-CoV*^[d](#TF1-4){ref-type="table-fn"}^*      *n* = 7                                                                                                              *n* = 6                                0.35
                                                    0.47                                          0.017                28                                                0.50      0.0063               79      
      ±*^[e](#TF1-5){ref-type="table-fn"}^*         0.011                                         0.0019                                                                 0.012     0.0006                       
      % error*^[f](#TF1-6){ref-type="table-fn"}^*   2                                             11                                                                     2         11                           
  SARS-CoV                                          *n* = 4*^[g](#TF1-7){ref-type="table-fn"}^*                                                                          *n* = 3                                0.32
                                                    0.73                                          0.03                 25                                                0.70      0.010                68      
      ±                                             0.017                                         0.003                6.3                                               0.015     0.0008               5.4     0.026
      % error                                       6                                             23                   25                                                11        3                    8       8
  SARS-CoV-2                                        *n* = 8                                                                                                              *n* = 3                                0.28
                                                    0.75                                          0.03                 23                                                0.74      0.0089               84      
      ±                                             0.019                                         0.003                4.4                                               0.023     0.0010               14.3    0.045
      % error                                       10                                            22                   20                                                4         18                   17      16
  EBOV                                              *n* = 3                                                                                                              *n* = 3                                4.0
                                                    0.80                                          0.72                 1.1                                               0.70      2.5                  0.28    
      ±                                             0.048                                         0.21                 0.065                                             0.047     0.76                 0.048   0.49
      % error                                       4                                             6                    6                                                 2         16                   17      12
  RSV*^[h](#TF1-8){ref-type="table-fn"}^*           *n* = 3                                                                                                              *n* = 3                                2.7
                                                    0.76                                          0.17                 4.5                                               0.82      0.50                 1.6     
      ±                                             0.022                                         0.023                                                                  0.027     0.089                        
      % error                                       3                                             14                                                                     3         18                           
  LASV                                              *n* = 3                                                                                                              *n* = 3                                20
                                                    0.57                                          0.11                 5.6                                               0.35      1.3                  0.29    
      ±                                             0.032                                         0.020                0.96                                              0.016     0.18                 0.059   4.7
      % error                                       2                                             18                   17                                                40        53                   20      24

*^a^ V*~max~ is a Michaelis--Menten parameter reflecting the maximal velocity of nucleotide incorporation.

*^b^ K~m~* is a Michaelis--Menten parameter reflecting the concentration of the nucleotide substrate at which the velocity of nucleotide incorporation is half of *V*~max~.

*^c^* Selectivity of a viral RNA polymerase for a nucleotide substrate analogue is calculated as the ratio of the *V*~max~/*K~m~* values for NTP and NTP analogue, respectively.

*^d^* Data from Gordon *et al.* ([@B17]).

*^e^* S.D. of the average.

*^f^* Percent error.

*^g^* All reported values have been calculated on the basis of a 9-data point experiment repeated the indicated number of times (*n*).

*^h^* Data from Tchesnokov *et al.* ([@B9]).

Selectivity of other nucleotide analogues against SARS-CoV-2 RdRp
-----------------------------------------------------------------

We determined selectivity values for various other nucleotide analogue inhibitors to provide a limited structure-activity relationship analysis with focus on SARS-CoV-2 RdRp ([Fig. 2](#F2){ref-type="fig"}). Selectivity for dATP, which lacks the 2′α-hydroxyl group, 2′-C-methylated compounds, and the broad-spectrum antivirals favipiravir and ribavirin were included in these studies ([Table 2](#T2){ref-type="table"}). A high selectivity value of ∼950-fold was measured for dATP, which shows that the enzyme efficiently discriminates against dNTPs as one would expect for an RNA polymerase. Similarly, the 2′β-hydroxyl in ara-ATP also translates in a high selectivity value (\>1000-fold). 2′-CMe-ATP contains a 2′β-methyl group, which shows a value of ∼170. 2-Deoxy-2′fluoro-CTP has been shown to exhibit antiviral activity against several RNA viruses ([@B20][@B21][@B23]). The selectivity value of 25 is relatively low compared with the aforementioned compounds and suggests that the 2′α-fluoro is largely tolerated by the enzyme. Sofosbuvir (SOF) is a uridine analogue that is approved for the treatment of hepatitis C virus (HCV) infection. The drug inhibits HCV RdRp ([@B24]). It contains a fluoro group at the 2′α-position and a methyl group at the 2′β-position. Here we measured a high selectivity value (∼1000-fold), which suggests that the 2′β-position may be the primary constraint for nucleotide incorporation by SARS-CoV-2 RdRp. The active triphosphate forms of favipiravir and ribavirin serve as substrates for several RdRp enzymes and mimic ATP and GTP ([@B25][@B26][@B30]). To compare efficiency of incorporation with RDV-TP, we measured selectivity values for incorporation opposite template uridine. High values of ∼500 and ≫1000, respectively, indicate that effective competition of these compounds with ATP is unlikely.

![**Chemical structures of ATP and ATP, CTP, and UTP nucleotide analogues used in this study.**](zbc9992023900002){#F2}

###### 

**Selectivity values for ATP, CTP, and UTP analogues against SARS-CoV-2 RdRp**

                                                                                          *V*~max~*^[a](#TF2-1){ref-type="table-fn"}^* (product fraction)   *K~m~^[b](#TF2-2){ref-type="table-fn"}^*   *V*~max~/*K~m~*   Selectivity*^[c](#TF2-3){ref-type="table-fn"}^*
  --------------------------------------------------------------------------------------- ----------------------------------------------------------------- ------------------------------------------ ----------------- -------------------------------------------------
                                                                                                                                                            μ*[m]{.smallcaps}*                                           *-fold*
  ATP*^[d](#TF2-4){ref-type="table-fn"}^* (*n* = 8*^[e](#TF2-5){ref-type="table-fn"}^*)   0.75                                                              0.03                                       23                Reference
      ±*^[f](#TF2-6){ref-type="table-fn"}^*                                               0.019                                                             0.004                                      4.4               
      % error*^[g](#TF2-7){ref-type="table-fn"}^*                                         10                                                                22                                         20                
  2′-CMe-ATP (*n* = 3)                                                                    0.84*^[f](#TF2-6){ref-type="table-fn"}^*                          6.4                                        0.13              173
      ±                                                                                   0.013                                                             0.37                                       0.007             8.9
      % error                                                                             1                                                                 5                                          5                 5
  dATP (*n* = 3)                                                                          0.63                                                              27                                         0.02              975
      ±                                                                                   0.021                                                             2.41                                       0.04              169
      % error                                                                             11                                                                28                                         16                17
  ara-ATP (*n* = 3)                                                                       0.56                                                              33                                         0.02              1329
      ±                                                                                   0.031                                                             4.06                                       0.01              371
      % error                                                                             15                                                                39                                         30                28
  ATP*^[h](#TF2-8){ref-type="table-fn"}^* (*n* = 3)                                       0.63                                                              0.04                                       14                Reference
      ±                                                                                   0.019                                                             0.006                                      1.3               
      % error                                                                             3                                                                 12                                         9                 
  Favipiravir-TP (*n* = 3) (as ATP analogue)                                              0.52                                                              21                                         0.03              570
      ±                                                                                   0.031                                                             3.9                                        0.02              230
      % error                                                                             7                                                                 41                                         52                40
  Ribavirin (*n* = 3) (as ATP analogue)                                                   NA*^[i](#TF2-9){ref-type="table-fn"}^*                            ≫g100                                      NA                ≫1000
      ±                                                                                                                                                                                                                  
      % error                                                                                                                                                                                                            
  CTP (*n* = 3)                                                                           0.72                                                              0.001                                      1022              Reference
      ±                                                                                   0.023                                                             8.8 × 10^−5^                               177               
      % error                                                                             1                                                                 18                                         17                
  2′d 2′ fluoro-CTP (*n* = 3)                                                             0.60                                                              0.02                                       37                29
      ±                                                                                   0.036                                                             0.003                                      8.5               7.6
      % error                                                                             17                                                                36                                         23                26
  UTP (*n* = 3)                                                                           0.75                                                              0.02                                       39                Reference
      ±                                                                                   0.021                                                             0.003                                      9.3               
      % error                                                                             4                                                                 22                                         24                
  SOF-TP (*n* = 3)                                                                        0.77                                                              21                                         0.04              1056
      ±                                                                                   0.030                                                             2.3                                        0.01              212
      % error                                                                             6                                                                 22                                         22                20

*^a^ V*~max~ is a Michaelis--Menten parameter reflecting the maximal velocity of nucleotide incorporation.

*^b^ K~m~* is a Michaelis--Menten parameter reflecting the concentration of the nucleotide substrate at which the velocity of nucleotide incorporation is half of *V*~max~.

*^c^* Selectivity of a viral RNA polymerase for a nucleotide substrate analogue is calculated as the ratio of the *V*~max~/*K~m~* values for NTP and NTP analogue, respectively.

*^d^* These experiments were conducted on RNA template compatible with \[α-^32^P\]GTP incorporation at position 5.

*^e^* All reported values have been calculated on the basis of a 9-data point experiment repeated the indicated number of times (*n*).

*^f^* S.D. of the average.

*^g^* Percent error.

*^h^* These experiments were conducted on RNA template compatible with \[α-^32^P\]CTP incorporation at position 5.

*^i^* NA, not available.

Structural model of nucleotide binding by SARS-CoV-2 RdRp
---------------------------------------------------------

To provide plausible explanations for our experimental measurements, we generated a model of an elongating SARS-CoV-2 RdRp complex ([Fig. 3](#F3){ref-type="fig"}). This model is based on the cryo-EM structure of the apo SARS-Co RdRp complex composed of nsp7, nsp8, and nsp12 ([@B19]). The active site is similar to other enzymes, for which ternary structures have been determined by X-ray crystallography, including HCV RdRp ([Fig. 3](#F3){ref-type="fig"}*A*), norovirus, and poliovirus RdRp ([@B24], [@B31], [@B32]). The catalytic metal ions in SARS-CoV-2 nsp12 are coordinated by a trio of aspartates, Asp-618, Asp-760, and Asp-761, and the substrate β-phosphate is stabilized by Arg-555. Converting Asp-760 and Asp-761 into Asn-760 and Asn-761 rendered the enzyme inactive ([Fig. 1](#F1){ref-type="fig"}). Of particular note, the residues Asp-623, Ser-682, and Asn-691 involved in 2′-OH recognition of the incoming nucleotide are conserved. However, whereas HCV, norovirus, and poliovirus RdRps use these serine and asparagine residues to coordinate the 2′-OH during incorporation, nsp12 appears to rely on an additional threonine residue (Thr-680) not present in the others enzymes ([Fig. 3](#F3){ref-type="fig"}*B*). This interaction has the effect of pulling the substrate deeper into the pocket. The lower positioning of the NTP in the active site is also seen in the interaction of the 3′-OH with the protein. In HCV RdRp, 3′-OH forms a hydrogen bond to the Asp-225 backbone NH, whereas in the coronaviruses, the model instead suggests that the β-phosphate coordinates to the analogous Asp-623 NH. As a consequence of this repositioning of the substrate, the activity of various inhibitors across the coronaviruses is expected to diverge from that seen with other polymerases. The preference for 2′-OH \> 2′d2′F ≫ 2′deoxy is evident from the nature of the polar residues coordinating that position and is similar to the other enzymes. In contrast, SOF-TP and 2′-CMe-ATP have increased clashes between the 2′β-Me and Asp-623 and Ser-682 ([Fig. 3](#F3){ref-type="fig"}*C*). This is partially relieved by a conformational change in Ser-682, but overall, the poorer incorporation efficiencies of the 2′β-Me--substituted inhibitors is likely due to these putative steric clashes. In contrast, RDV-TP ([Fig. 3](#F3){ref-type="fig"}*D*) is recognized at the 2′-OH in a manner similar to ATP, and the 1′-CN modification is well-positioned in a pocket formed between Thr-687 and Ala-688. The high efficiency of incorporation reported here is consistent with this model.

![*A*, X-ray structure of HCV RdRp with an incoming nonhydrolyzable ADP substrate (PDB entry [4WTD](4WTD)). The 2′-OH of the substrate is recognized by the trio of residues, Asp-225, Ser-282, and Asn-291, with hydrogen bonds formed to Ser-282 and Asn-291 in this preincorporation state. *B*, model of SARS-CoV-2 nsp12 with incoming ATP. In addition to the analogous Asp/Ser/Asn residues, Thr-680 is positioned to alter the hydrogen-bonding network and effectively pull the substrate lower into the pocket relative to NS5B. *C*, model of SARS-CoV-2 with SOF-TP. The greater occlusion of the 2′ position due to Asp-623 and Ser-682 makes 2′β-methyl substitution less effective than with NS5B. *D*, model of SARS-CoV-2 with remdesivir-TP. The remdesivir 1′CN sits in a pocket formed by residues Thr-687 and Ala-688. Residues Asp-623 and Ser-682 (not shown) adopt the same conformations as with ATP.](zbc9992023900003){#F3}

Patterns of inhibition of RNA synthesis by RDV-TP
-------------------------------------------------

The incorporation of a nucleotide analogue into the growing RNA chain does not necessarily translate into inhibition. To determine the patterns of inhibition of RNA synthesis, we devised two RNA templates that contain single or multiple sites of incorporation (template uridines) ([Fig. 4](#F4){ref-type="fig"}*A*). These sequences were used to compare the inhibitory effects of RDV-TP against MERS-CoV, SARS-CoV, SARS-CoV-2, and LASV RdRp. The latter enzyme showed a significantly higher selectivity value for RDV-TP ([Table 1](#T1){ref-type="table"}), and RDV does not show antiviral activity against LASV ([@B10]). For CoV RdRp complexes with templates allowing multiple incorporations, we observe termination of RNA synthesis at positions *i*+3 and *i*+4. A faint band representing the full-length product suggests low levels of read-through ([Fig. 4](#F4){ref-type="fig"}*B*). On a template that allows only a single RDV-TP incorporation, termination is seen solely at position *i*+3. Full-length product formation is generally more pronounced under these conditions, following the order MERS-CoV RdRp \> SARS-CoV RdRp \> SARS-CoV-2 RdRp. For LASV RdRp, RNA synthesis patterns in the presence or absence of the nucleotide analogue are very similar. Chain termination or delayed chain termination is not evident. To further investigate the possibility of long-range effect of RDV-TP incorporation, we used a 26-mer RNA template and did not observe any change in the pattern of RNA synthesis ([Fig. S3](https://www.jbc.org/cgi/content/full/RA120.013679/DC1)). Hence, LASV L protein is likely not inhibited by RDV-TP.

![**Patterns of inhibition of RNA synthesis with RDV-TP.** *A*, RNA primer/template substrates used to test multiple (*left*) or single (*right*) incorporations of RDV-TP. *G* indicates incorporation of the radiolabeled nucleotide opposite template position 5. RDV-TP incorporation is indicated by *i*. RDV-TP incorporation was monitored with purified CoV RdRp complexes (*B*) and LASV L protein (*C*) in the presence of the indicated combinations of NTPs and RDV-TP.](zbc9992023900004){#F4}

Examination of the structural model suggests that the primer with the incorporated RDV can translocate without obstruction to position *i*+1 ([Fig. 5](#F5){ref-type="fig"}, *A* and *B*). Similarly, no obstructions can be discerned at the *i*+2 ([Fig. 5](#F5){ref-type="fig"}*C*) or *i*+3 ([Fig. 5](#F5){ref-type="fig"}*D*). This would allow the incorporation of three subsequent nucleotides, in agreement with our experimental data. However, at position *i*+4 ([Fig. 5](#F5){ref-type="fig"}, *E* and *F*), a steric clash is seen between the 1′-CN substituent of RDV and residue Ser-861. The serine O is only 1.7 Å from the 1′-CN N. The short distance is expected to lead to a significant distortion of the positioning of the RNA, hampering translocation to the *i*+4 position.

![**A steric clash between the incorporated RDV and Ser-861 prevents enzyme translocation at *i*+3.** *A--D*, the primer with the incorporated RDV (*green*) translocates without obstruction from the substrate position *i* through *i*+3, allowing incorporation of three subsequent nucleotides (*yellow*). *E*, at *i*+4, the 1′-CN moiety of RDV encounters a steric clash with Ser-861 of nsp12. *F*, this clash likely prevents the enzyme from advancing into *i*+4.](zbc9992023900005){#F5}

Overcoming of the delayed chain termination by incorporated RDV
---------------------------------------------------------------

Read-through at a site of delayed chain termination may reduce the inhibitory effect of RDV-TP. We therefore tested whether termination of RNA synthesis could be overcome with time or with increasing concentrations of nucleotide pools ([Fig. 6](#F6){ref-type="fig"}). In the presence of equivalent concentrations of RDV-TP and UTP (0.1 μ[m]{.smallcaps}), which is the next nucleotide to be incorporated following the RDV-TP incorporation site and also following the site of delayed chain termination, the full-length product formation is negligible. The signal for delayed chain termination is not alleviated with time, which provides more evidence for a *bona fide* termination site and not enzyme pausing ([Fig. 6](#F6){ref-type="fig"}*A*, *left*). In contrast, full-length product formation is time-dependent when ATP replaces RDV-TP in the reaction mixture ([Fig. 6](#F6){ref-type="fig"}*A*, *middle*). As expected, the omission of both ATP and RDV-TP prevents RNA synthesis beyond product 5, thus controlling for C:U and U:U misincorporations under the present reaction conditions ([Fig. 6](#F6){ref-type="fig"}*A*, *right*). However, delayed chain termination can be overcome with higher NTP concentrations. In the presence of increasing concentrations of UTP, the signal at *i*+3 decreases concomitantly with an increase in the full-length product. UTP concentrations that are ∼100-fold higher than RDV-TP can cause significant reductions in delayed chain termination ([Fig. 6](#F6){ref-type="fig"}*B*).

![**Overcoming of delayed chain termination.** The RNA primer/template substrate used in this assay is shown *above* the gels. *G* indicates incorporation of the radiolabeled nucleotide opposite template position 5. Position *i* allows incorporation of ATP or RDV-TP. RNA synthesis was monitored with purified SARS-CoV-2 RdRp complex in the presence of indicated concentrations of NTP mixtures. *A*, time dependence of delayed chain termination. *B*, overcoming delayed chain termination with increasing concentrations of UTP.](zbc9992023900006){#F6}

Discussion
==========

RDV is an investigational nucleotide analogue with a broad spectrum of antiviral activities against several RNA viruses, including filoviruses and coronaviruses ([@B5], [@B8], [@B10], [@B12][@B13][@B14]). Studies in mice and rhesus macaques have helped to assess the therapeutic potential of this drug against EBOV, SARS-CoV, and MERS-CoV ([@B8], [@B13][@B14][@B15]). Antiviral activity of RDV has also been demonstrated against SARS-CoV-2 in cell culture ([@B33]), whereas data from animal models and clinical trials are pending. Moreover, it remains to be seen whether the mechanism of inhibition described for EBOV RdRp and MERS RdRp is also relevant for SARS-CoV-2. Here, we expressed and purified active SARS-CoV-2 RdRp to study RNA synthesis and its inhibition by RDV-TP. Based on our biochemical data, we propose a unifying, refined mechanism of inhibition of SARS-CoV, MERS-CoV, and SARS-CoV-2 ([Fig. 7](#F7){ref-type="fig"}).

![**Mechanism of inhibition of CoV RdRp by RDV-TP.** *1*, the priming strand is shown with *green circles*, *colorless circles* represent residues of the template, and the *blue oval* represents the active CoV RdRp complex. This is a *schematic representation* of a random elongation complex. The footprint of RdRp on its primer/template is unknown. *2*, competition of RDV-TP with its natural counterpart ATP opposite template uridine (*U*). The incorporated nucleotide analogue is illustrated by the *red circle. 3*, RNA synthesis is terminated after the addition of three more nucleotides, which is referred to as delayed chain termination. *4*, delayed chain termination can be overcome by high ratios of NTP/RDV-TP.](zbc9992023900007){#F7}

Co-expression of SARS-CoV-2 nsp5, nsp7, nsp8, and nsp12 in insect cells yields an active RdRp complex composed of nsp8 and nsp12. The same data were obtained with MERS-CoV and SARS-CoV. RNA synthesis was monitored on short primer/templates that mimic the elongation stage ([Fig. 7](#F7){ref-type="fig"}, *step 1*). We initially compared the efficiency of incorporation of RDV-TP with its natural counterpart ATP ([Fig. 7](#F7){ref-type="fig"}, *step 2*). A steady-state kinetic approach was employed to translate our findings into quantitative terms and to facilitate comparisons among the various enzymes and compounds tested. Efficiency of incorporation of the natural nucleotide over the nucleotide analogue defines selectivity. For RDV-TP, we measured selectivity values of ∼0.3 with SARS-CoV, SARS-CoV-2, and previously also with MERS-CoV RdRp. SARS-CoV and SARS-CoV-2 both belong to the betacoronaviruses of the B lineage, and the nsp 12-amino acid sequences of the two viruses are 96% identical. In contrast, MERS-CoV belongs to the betacoronaviruses of the C lineage and is only 71% identical with SARS-CoV-2. Despite greater sequence variations, RdRp motifs that play important roles in substrate binding and catalysis are highly conserved among the three coronaviruses ([Fig. S2](https://www.jbc.org/cgi/content/full/RA120.013679/DC1)). Hence, interactions with nucleotide analogue inhibitors are expected to be similar, and our selectivity data provide experimental evidence for this notion. In contrast, selectivity values for RDV-TP against EBOV and RSV RdRp are between 2 and 5, and LASV RdRp shows even higher selectivity values of ∼20. Whereas the active sites of EBOV and RSV enzymes still share a number of key residues within the classic polymerase motifs, LASV RdRp shows substantial differences when these motifs are compared with EBOV and RSV and also with SARS-CoV, SARS-CoV-2, and MERS-CoV ([Fig. S2](https://www.jbc.org/cgi/content/full/RA120.013679/DC1)).

We have evaluated several other nucleotide analogues using the same protocol with a focus on SARS-CoV-2 RdRp ([Fig. 2](#F2){ref-type="fig"} and [Table 2](#T2){ref-type="table"}). The selectivity of ATP over dATP is ∼1000, which shows that the enzyme effectively discriminates against deoxyribonucleotides that are substrates for DNA polymerases. Similar results were obtained with the broad spectrum antivirals favipiravir and ribavirin ([@B26], [@B27], [@B30]). These compounds show high selectivity values of ∼500 and ∼10,000 in favor of ATP. Compounds with modifications at the 2′β-position are also associated with high selectivity values in favor of the natural nucleotide. SOF-TP and 2′-CMe-ATP show selectivity values of ∼1000 and ∼170 in favor of UTP and ATP, respectively. Selectivity of ATP over ara-ATP is likewise high (∼1000). A homology model of SARS-CoV-2 points to a putative steric clash of 2′β-modifications with residues Asp-623 and Ser-682. With the limitations of a steady-state approach, we are unable to ascribe differences in selectivity measurements solely to inhibitor binding; however, whereas the model is not based on structural data of SARS-CoV-2 RdRp, it provides a plausible explanation for our experimental observations.

RDV-TP is a nonobligate chain terminator, which contains a 3′-hydroxyl group that may still form a phosphodiester bond with the next incoming nucleotide. Indeed, as demonstrated for RdRp enzymes from RSV, EBOV, NiV, and MERS, delayed chain termination provides a likely mechanism of action ([@B7][@B8][@B9], [@B17]). For all three coronavirus RdRp complexes, we observe a specific termination site at position *i*+3 ([Fig. 7](#F7){ref-type="fig"}, *step 3*). The structural reasons for the precise termination event remain to be elucidated; however, the underlying mechanism is likely to be common to all three coronaviruses if we consider the identical patterns of inhibition. At *i*+4, our model predicts a steric clash between the 1′-CN substituent of the incorporated RDV and residue Ser-861. This model is consistent with the observed termination at *i*+3 and the inability of the enzyme to translocate a single position further downstream to accommodate the next nucleotide. Sequences extracted from GenBank^TM^ reveal that this serine residue is conserved across all alpha-, beta-, and deltacoronaviruses.

Termination of RNA synthesis can be overcome by higher concentrations of the natural nucleotide pools ([Fig. 7](#F7){ref-type="fig"}, *step 4*). NTP can reach low millimolar concentrations ([@B34], [@B35]). The intracellular concentration of RDV-TP can vary between low and high micromolar levels in relevant cell cultures ([@B8], [@B14]), and high ratios of NTP/RDV-TP are likely detrimental to inhibition. However, the efficient incorporation of RDV-TP into the growing RNA chain may also provide a mechanism that counteracts reduced termination in the presence of high NTP concentrations. Our data confirm that consecutive and/or multiple sites of incorporation of RDV-TP increase termination and in turn inhibition; however, the efficiency of this effect remains to be determined ([Fig. S2*B*](https://www.jbc.org/cgi/content/full/RA120.013679/DC1)). Another factor that can reduce the potency of nucleotide analogues is the 3′-5′ exonuclease activity of nsp14 ([@B6], [@B36][@B37][@B38]). This enzyme displays proofreading activity in conjunction with nsp10 ([@B36], [@B37], [@B39]). In this context, we have recently proposed that the additional three nucleotides that follow the incorporated RDV may provide protection from excision ([@B17], [@B40]). Future studies that take into account rates of nucleotide incorporation, rates of excision of multiple nucleotides, and the likelihood of RDV-TP reincorporation will be required to address this problem.

Several independent examples point to a significant correlation between the efficiency of selective incorporation of a given nucleotide analogue and the corresponding antiviral effect measured in cell culture. Half-maximal effective concentrations (EC~50~) of RDV against coronaviruses and filoviruses are in the submicromolar range, which is unusually low for a compound with a broad spectrum of antiviral activity ([@B8], [@B10], [@B12], [@B14], [@B41]). High potency in cell culture correlates with highly effective incorporation of RDV-TP with EBOV RdRp and, even more so, with the three coronavirus enzymes. Conversely, RDV shows a weak antiviral effect against LASV ([@B10]), and our biochemical data revealed low rates of incorporation by LASV RdRp. In this context, it is also important to note that our previous measurements with human mitochondrial RNA polymerase revealed high selectivity of ATP over RDV-TP ([@B9]), which is consistent with low levels of cytotoxicity of RDV ([@B8], [@B14]). Favipiravir-TP and ribavirin-TP are also less well-incorporated by SARS-CoV-2 RdRp. This is also evident with a template that offers multiple incorporation sites ([Fig. S2*B*](https://www.jbc.org/cgi/content/full/RA120.013679/DC1)). In cell culture, these inhibitors often show EC~50~ values in the higher micromolar range depending on the nature of the RNA virus ([@B26], [@B41], [@B42]). High concentrations of favipiravir and ribavirin were also required to reduce infection with SARS-CoV-2 (EC~50~ = 109.50 μ[m]{.smallcaps} and EC~50~ = 61.88 μ[m]{.smallcaps}, respectively) ([@B33]). Moreover, ribavirin does not seem to provide clinical benefits in the context of SARS-CoV and MERS-CoV infection ([@B41]), 2′-CMe-ATP is not utilized as a substrate by EBOV RdRp, and 2′-C-methylated compounds show no significant antiviral effects in mini-genome replicons of EBOV ([@B43]). Equivalent studies are not yet available for coronaviruses; however, the high selectivity for the natural nucleotides over SOF-TP and 2′-CMe-ATP would not predict a potent antiviral effect.

In conclusion, the combined data provide evidence for a unifying mechanism of inhibition of RDV-TP against coronavirus RdRp. Favorable selectivity for the nucleotide analogue over its natural counterpart ATP and delayed chain termination at position *i*+3 are key elements of inhibition observed with SARS-CoV, MERS-CoV, and SARS-CoV-2 RdRp complexes. The availability of human safety data along with the antiviral studies in cell culture and in animal models as well as a clear mechanism of action provide a large body of evidence to justify the ongoing clinical trials with RDV for the treatment of COVID-19 ([@B8], [@B10], [@B12][@B13][@B17], [@B33]). The refined biochemical mechanism described in this study characterizes RDV as a direct-acting antiviral (DAA). This term was previously introduced to describe newer classes of HCV drugs that target a specific process in the viral life cycle ([@B44]), as opposed to older treatments with interferon and ribavirin that have been associated with multiple possible mechanisms ([@B45]). Compounds that are currently considered as potential treatments for COVID-19 include drugs approved for other conditions, repurposed drugs, and inhibitors with a broad spectrum of antiviral activities. Research into underlying mechanisms is needed to classify any of these compounds as a DAA.

Experimental procedures
=======================

Nucleic acids and chemicals
---------------------------

All RNA primers and templates used for in this study were 5′-phosphorylated and purchased from Dharmacon (Lafayette, CO). 2′-CMe-ATP, RDV-TP, and SOF-TP were provided by Gilead Sciences (Foster City, CA). Ara-ATP, 2′deoxy-2′fluoro-CTP was purchased from TriLink (San Diego, CA). Ribavirin-TP was purchased from Jena Bioscience (Jena, Germany). Favipiravir-TP was purchased from Toronto Research Chemicals (North York, Ontario, Canada). NTPs and dATP were purchased from GE Healthcare. \[α-^32^P\]GTP was purchased from PerkinElmer Life Sciences.

Protein expression and purification
-----------------------------------

The pFastBac-1 (Invitrogen, Burlington, Ontario, Canada) plasmid with the codon-optimized synthetic DNA sequences (GenScript, Piscataway, NJ) coding for a portion of 1ab polyproteins of SARS-CoV (NCBI: AAP33696.1) and SARS-CoV-2 (NCBI: QHD43415.1) containing only nsp5, nsp7, nsp8, and nsp12 were used as a starting material for protein expression in insect cells (Sf9, Invitrogen). We employed the MultiBac (Geneva Biotech, Indianapolis, IN) system for protein expression in insect cells (Sf9, Invitrogen) according to published protocols ([@B46], [@B47]). SARS-CoV and SARS-CoV-2 protein complexes were purified using nickel-nitrilotriacetic acid affinity chromatography of the nsp8 N-terminal 8-histidine tag according to the manufacturer\'s specifications (Thermo Scientific). Expression and purification of EBOV RdRp complex were performed as described previously ([@B48]). LASV L protein full-length (NCBI: AIT17397.1) was also expressed in insect cells through the Baculovirus expression system and purified using Strep-Tactin affinity chromatography (IBA Lifesciences, Göttingen, Germany) of the N-terminal Strep-tag according to the manufacturer\'s specifications (IBA Lifesciences). The identities of the purified LASV, SARS-CoV, and SARS-CoV-2 proteins were confirmed by MS analysis (Dr. Jack Moore, Alberta Proteomics and Mass Spectrometry, Edmonton, Alberta, Canada).

Evaluation of RNA synthesis and inhibition studies
--------------------------------------------------

RNA synthesis assays, data acquisition, and quantification were done as previously reported by us ([@B9], [@B17], [@B48]). The following 5′-monophosphorylated RNA templates were used in this study (the portion of the template that is complementary to the 4-nt primer is underlined): 3′-[UGCG]{.ul}CUAGAAAAAAp for measurements of the selectivity values of ATP analogues and determination of the patterns of inhibition with the incorporated RDV at a single position; 3′-[UGCG]{.ul}CUAGAGAGAGAGAGAGAGAGAGp for determination of the pattern of inhibition of LASV RdRp with the incorporated RDV at a single position but on a 26-nt template; 3′-[UGCG]{.ul}CUUGUAUAUUp for determination of the patterns of inhibition with the consecutively incorporated RDV; 3′-[UGCG]{.ul}GUACUUUAUUp for measurements of the selectivity values of favipiravir-TP and ribavirin-TP; 3′-[UGCG]{.ul}CGUAAAAAAAp for measurements of the selectivity values of 2′-d2′fluoro-CTP, and 3′-[UCGC]{.ul}GAUCUUUAUU for measurements of the selectivity values of sofosbuvir-TP.

Briefly, RNA synthesis assay consisted of mixing (final concentrations) Tris-HCl (pH 8, 25 m[m]{.smallcaps}), RNA primer (200 μ[m]{.smallcaps}), RNA template (2 μ[m]{.smallcaps}), \[α-^32^P\]NTP (0.1 μ[m]{.smallcaps}), various concentrations and combinations (as indicated) of NTP and NTP analogues, and MERS-, SARS- and SARS-CoV-2 RdRp complex (∼0.1 μ[m]{.smallcaps}) on ice. Reactions with LASV L protein contained ∼0.02 μ[m]{.smallcaps} enzyme. Reaction mixtures (10 μl) were incubated for 10 min at 30 °C followed by the addition of 5 μl of MgCl~2~ (5 m[m]{.smallcaps}). Reactions were stopped after 30 min by the addition of 15 μl of formamide/EDTA (50 m[m]{.smallcaps}) mixture and incubated at 95 °C for 10 min. Data were collected and analyzed using GraphPad Prism 7.0 (GraphPad Software, Inc., San Diego, CA) as reported previously ([@B9], [@B17], [@B48]). Our assay involves incorporation of \[α-^32^P\]GTP into the primer. With this approach, it is not possible to quantify the fraction of the extended primer; however, the reaction products are clearly defined by the correct incorporation of \[α-^32^P\]GTP.

Structural model of elongating SARS-CoV-2 nsp12
-----------------------------------------------

A model of the SARS-CoV-2 replication complex in its elongating state was constructed based on the recent cryo-EM structure of the apo-SARS-CoV nsp12/nsp7/nsp8 complex (PDB entry [6NUR](6NUR)) ([@B1]). With high sequence identity (nsp12 = 96%, nsp7 = 98%, nsp8 = 97%), a homology model was generated with Prime ([@B49], [@B50]). To this, an X-ray structure of HCV RdRp in its elongating state (PDB entry [4WTD](4WTD)) ([@B3]) was aligned to the SARS-CoV-2 model. Rather than doing a whole structure alignment, key residues that interact with the RNA in the RNA binding channel were aligned. These include Ala-97, Phe-193, Gly-283, and Ser-367 in NS5B and Ser-501, Gly-590, Gly-683, and Ser-814 in nsp12. The two Mn^2+^ ions and the ADP substrate from the HCV RdRp structure were changed to Mg^2+^ and ATP, and these, as well as the aligned RNA, were added to the SARS-CoV-2 model. Several active-site residues were manually adjusted to accommodate the incoming metals and substrate following the NS5B structure. These residues include Lys-545, Arg-555, Asp-618, Ser-682, Gly-683, Asp-760, and Asp-761. This was followed by a series of constrained optimizations in both Prime and Macromodel (Schrödinger, LLC, New York). The process was repeated several times using different types of constraints, and each time a similar model resulted. RDV-TP and other inhibitors were modeled into the nsp12 active site, allowing only limited protein flexibility. Homology models of other coronaviruses, including SARS and MERS, were generated from this model with Prime.

Data availability
-----------------

All data are included within this article.
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